ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug–Oct, ACP-211 Next Year

ACADIA Pharmaceuticals (NASDAQ: ACAD) executives discussed upcoming clinical readouts and pipeline priorities during the company's virtual CNS conference, with a focus on remlifanserin (formerly ACP-204) in Alzheimer's disease psychosis (ADP), an ongoing Phase 2 program in Lewy body dementia psychosis, and ACP-211 in major depressive disorder (MDD). Remlifanserin positioned as "next-generation" follow-on to pimavanserin Liz Thompson,